Lupin rose 0.75% to Rs 1,479.55 at 12:43 IST on BSE after the company announced that it has launched its Voriconazole Tablets, 50 mg & 200 mg and Voriconazole Oral Suspension, 40 mg/ml in the US.
The announcement was made during market hours today, 19 December 2016.Meanwhile, the S&P BSE Sensex was down 66.58 points or 0.25% at 26,422.98
On the BSE, 23,000 shares were traded on the counter so far as against the average daily volumes of 94,617 shares in the past one quarter. The stock had hit a high of Rs 1,493.80 and a low of Rs 1,460 so far during the day. The stock had hit a 52-week high of Rs 1,911.55 on 9 February 2016. The stock had hit a 52-week low of Rs 1,294.05 on 29 March 2016. The stock had outperformed the market over the past 30 days till 16 December 2016, rising 3.93% compared with the 1% rise in the Sensex. The scrip also outperformed the market in past one quarter, declining 4.52% as against Sensex's 7.38% decline.
The large-cap company has equity capital of Rs 90.28 crore. Face value per share is Rs 2.
Lupin announced today, 19 December 2016 that it has launched its Voriconazole Tablets, 50 mg and 200 mg and Voriconazole Oral Suspension, 40 mg/ml having received an approval from the United States Food and Drug Administration (USFDA) earlier to market a generic equivalent of PF Prism C.V's Vfend Tablets, 50 mg and 200 mg and Vfend Oral Suspension, 40 mg/ml.
Voriconazole Tablets, 50 mg and 200 mg and Voriconazole Oral Suspension, 40 mg/ml are the AB rated generic equivalent of PF Prism C.V's Vfend Tablets, 50 mg and 200 mg and Vfend Oral Suspension, 40 mg/ml. It is indicated for use in patients 12 years of age and older in the treatment of various fungal infections. Vfend Tablets, 50 mg & 200 mg had annual US sales of $81 million as per the IMS MAT September 2016 data while Vfend Oral Suspension, 40 mg/ml had annual US sales of $15.2 million as per the IMS MAT September 2016 data.
Lupin's consolidated net profit jumped 57.76% to Rs 662.19 crore on 31.9% rise in net sales to Rs 4211.18 crore in Q2 September 2016 over Q2 September 2015.
Also Read
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, central nervous system (CNS), GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content